Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind placebo-controlled dose-finding study of ME3113 (udenafil) in benign prostatic hyperplasia with lower urinary tract symptoms
jRCT2080221911Phase 2
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing ME3113 oral dose groups with Placebo oral (2 arms).
02
Drugs
udenafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on jRCT2080221911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221911.